Tissue microarrays para testar as proteínas basais no câncer de mama familiar
Palavras-chave:
Câncer da mama, Marcadores biológicos, Marcadores genéticos, Imunohistoquímica, Doenças genéticas inatasResumo
CONTEXTO E OBJETIVO: As proteínas p63, p-cad e CK 5 são expressas em células basais/mioepiteliais da mama. Entretanto a expressão dessas proteínas no câncer esporádico e familiar ainda não é bem conhecida. O objetivo do estudo foi estudar essas proteínas no câncer de mama, utilizando a técnica de tissue microarray, assim como ER e HER2. TIPO DE ESTUDO E LOCAL: Estudo transversal, realizado no Centro de Atenção Integral à Saúde da Mulher, Universidade Estadual de Campinas, Brasil, e no Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Portugal. MÉTODOS: O estudo analisou a expressão das proteínas p63, CK 5, p-cad, ER e HER2 numa série de 168 casos de câncer de mama. Os critérios utilizados para identifi car as mulheres com alto risco foram os do Breast Cancer Linkage Consortium. RESULTADOS: A série de câncer familiar foi freqüentemente mais positiva para as proteínas basais p-cadherin (p = 0,0004), p63 (p < 0,0001) e CK 5 (p < 0,0001) que o câncer esporádico. A presença da co-expressão das proteínas basais CK 5+/p63+, agrupados dois a dois, foi associada com o fenótipo do câncer familiar (odds ratio, OR = 34,34), enquanto que sua ausência foi com o câncer esporádico (OR = 0,13). CONCLUSÕES: O câncer da mama familiar está associado aos marcadores de células basais proteínas p63, p-cad e CK 5, utilizando-se a técnica de tissue microarray. Por fi m, parece legítima a interpretação destes resultados como mais uma evidência que suporta a hipótese da existência de células precursoras do câncer familiar da mama. O conhecimento dos perfi s de expressão destas células, bem como das vias de sinalização envolvidas, benefi ciarão o entendimento da carcinogênese mamária.
Downloads
Referências
Deugnier MA, Teuliere J, Faraldo MM, Thiery JP, Glukhova MA. The importance of being a myoepithelial cell. Breast Cancer Res. 2002;4(6):224-30.
Birnbaum D, Bertucci F, Ginestier C, Tagett R, Jacquemier J, Charafe-Jauffret E. Basal and luminal breast cancers: basic or luminous? (review). Int J Oncol. 2004;25(2):249-58.
Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52.
DiRenzo J, Signoretti S, Nakamura N, et al. Growth factor require- ments and basal phenotype of an immortalized mammary epithelial cell line. Cancer Res. 2002;62(1):89-98.
van’t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530-6.
SorlieT, Wang Y, Xiao C, et al. Distinct molecular mechanisms underly- ing clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics. 2006;7:127.
Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nature Rev Cancer. 2002;2(2):101-12.
Callagy G, Cattaneo E, Daigo Y, et al. Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol. 2003;12(1):27-34.
Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 2005;447(4):688-94.
Bocker W, Moll R, Poremba C, et al. Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest. 2002;82(6):737-46.
Boecker W, Buerger H. Evidence of progenitor cells of glandular and myoepithelial cell lineages in the human adult female breast epithelium: a new progenitor (adult stem) cell concept. Cell Prolif. 2003;36(Suppl 1):73-84.
Reis-Filho JS, Simpson PT, Martins A, Preto A, Gartner F, Schmitt FC. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch. 2003;443(2):122-32.
McKeon F. p63 and the epithelial stem cell: more than status quo? Genes Dev. 2004;18(5):465-9.
Westfall MD, Pietenpol JA. p63: Molecular complexity in devel- opment and cancer. Carcinogenesis. 2004;25(6):857-64.
Peralta Soler A, Knudsen KA, Salazar H, Han AC, Keshgegian AA. P-cadherin expression in breast carcinoma indicates poor survival. Cancer. 1999;86(7):1263-72.
Paredes J, Milanezi F, Reis-Filho JS, Leitão D, Athanazio D, Schmitt F. Aberrant P-cadherin expression: is it associated with estrogen-independent growth in breast cancer? Pathol Res Pract. 2002;198(12):795-801.
Han AC, Soler AP, Knudsen KA, Salazar H. Distinct cadherin profiles in special variant carcinomas and other tumors of the breast. Hum Pathol. 1999;30(9):1035-9.
Gamallo C, Moreno-Bueno G, Sarrió D, Calero F, Hardisson D, Palacios J. The prognostic significance of P-cadherin in infiltrat- ing ductal breast carcinoma. Mod Pathol. 2001;14(7):650-4.
Madhavan M, Srinivas P, Abraham E, et al. Cadherins as predic- tive markers of nodal metastasis in breast cancer. Mod Pathol. 2001;14(5):423-7.
Palacios J, Honrado E, Osorio A, et al. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res. 2003;9(10 Pt 1):3606-14.
Palacios J, Honrado E, Osorio A, Diez O, Rivas C, Benítez J. Re: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2004;96(9):712-4.
Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet. 1997;349(9064):1505-10.
Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62(3):676-89.
Reis-Filho JS, Milanezi F, Paredes J, et al. Novel and classic myoepi- thelial/stem cell markers in metaplastic carcinomas of the breast. Appl Immunohistochem Mol Morphol. 2003;11(1):1-8.
Altman DG. Practical statistics for medical research. London: Chapman & Hall; 1991.
Foulkes WD. BRCA1 functions as a breast stem cell regulator. J Med Genet. 2004;41(1):1-5.
Warnberg F, Nordgren H, Bergkvist L, Holmberg L. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. Br J Cancer. 2001;85(6):869-74.
Aubele MM, Cummings MC, Mattis AE, et al. Accumulation of chromosomal imbalances from intraductal proliferative lesions to adjacent in situ and invasive ductal breast cancer. Diagn Mol Pathol. 2000;9(1):14-9.
Farabegoli F, Champeme MH, Bieche I, et al. Genetic pathways in the evolution of breast ductal carcinoma in situ. J Pathol. 2002;196(3):280-6.
Lee JS, John EM, McGuire V, et al. Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations. Cancer Epidemiol Biomarkers Prev. 2006;15(2):359-63.
Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005;11(14):5175-80.
Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003;95(19):1482-5.
Tischkowitz MD, Foulkes WD. The basal phenotype of BRCA1-related breast cancer: past, present and future. Cell Cycle. 2006;5(9):963-7.
Downloads
Publicado
Como Citar
Edição
Seção
Licença

Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.